Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 versus best supportive care in MDS/MPN overlap syndromes
ISRCTN30808508Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and chronic myelomonocytic leukemia (CMML) comparing ASTX727 with Best supportive care (2 arms). Primary endpoint: Best overall response at end of cycle 6. Started May 2022; status: active, not recruiting.
02
Drugs
inqovi
03
Conditions
myelodysplastic/myeloproliferative neoplasm (MDS/MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ISRCTN30808508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN30808508.